The content on this site is intended for healthcare professionals only
Dr Baird outlines the background of the POSEIDON trial of the EurocanPlatform project, an investigator-led trial in metastatic breast cancer that is hormone receptor positive and HER2-negative. The trial is examining a combination of Tamoxifen with PI-3 kinase inhibitor.
EurocanPlatform is an EC funded project bringing together 28 European cancer Institutions and organisations to work together in a unique collaboration. The centres are sharing infrastructures and collaborating on projects to help advance cancer research and treatment.
He explains how the EurocanPlatform project has been instrumental in bringing the trial to life, what challenges have been faced and what they expect for the remainder of the trial in the future.
Watch this video on the highlights of the project.
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer
CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo
ASCO 2023: Breast cancer research highlights
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
Breast and emerging indications for IORT
